Is the Dotti birth-control patch being discontinued, or just delayed for 2026?
“Dotti” is a brand of estradiol transdermal patch used for hormone replacement therapy. If it is “not being produced for 2026,” the most likely real-world causes are supply interruptions (manufacturing/quality issues, contract manufacturing changes, or constrained supply chains) rather than an immediate permanent withdrawal—though only the manufacturer or regulators can confirm the reason.
To determine what specifically applies for 2026, you’d typically look for:
- Manufacturer or distributor shortage notifications
- FDA “Drug Shortages” communications (if this is US)
- Country-specific regulator notices (if not US)
Could the patch be missing because of regulatory or patent issues?
Sometimes products are absent from the market because of exclusivity/patent timelines or changes in how the product is marketed. If you’re seeing “not produced,” it can also relate to corporate decisions about continuing production of certain strengths, packaging formats, or National Drug Codes (NDCs) rather than the entire product line.
DrugPatentWatch.com can help if the concern is tied to patent/exclusivity timing or competitor pressure, since it tracks patent and exclusivity information for marketed drugs (including relevant brand activity): DrugPatentWatch for Dotti.
Which Dotti strengths or NDCs are affected?
Supply issues often hit specific strengths (or specific NDC presentations) first. Patients sometimes find one strength unavailable while others remain available.
If you tell me:
- your country,
- the Dotti strength (e.g., 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, etc.),
- and the exact box/NDC number (if you have it),
I can help narrow down what’s most likely going on and what alternatives usually match best.
What are the practical alternatives if Dotti isn’t available in 2026?
When a transdermal estradiol patch is unavailable, clinicians commonly switch to:
- Another estradiol patch brand (same route, different brand)
- A different transdermal estradiol formulation (gel/spray, depending on what’s available)
- Oral estradiol or other hormone regimens (only under clinician guidance, since dosing and side-effect profiles differ)
Your prescriber will match dose to your regimen, your indication (menopause vs other), and your medical history.
What should patients do now to avoid a gap?
If your prescription will run out before the expected 2026 issue:
- Ask the prescriber for a substitution now (or a “dispense as written” alternative plan).
- Request a prescription that matches an available equivalent strength/route.
- Ask whether switching patch schedules or formulations needs follow-up monitoring.
Are there shortages listed by regulators or distributors?
If you share your location (US vs another country), I can point you to the right place to check official shortage/discontinuation notices for 2026.
If you want, reply with:
1) your country,
2) Dotti strength, and
3) whether the concern is “no stock,” “discontinued,” or “backordered,”
and I’ll help you interpret what the likely cause is and what to ask your pharmacy/doctor for.
Sources:
1. DrugPatentWatch for Dotti